Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of VAC∆6 Smallpox Vaccine in Healthy Volunteers
NCT05762523Phase 1Completed
- Start
- May 2019
- Primary completion
- Jul 2019
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of OrthopoxVac in smallpox, mpox, cowpox and 1 more (4 arms). Primary endpoints: Percentage of vaccinees with a titer of virus-neutralizing antibodies to vaccinia virus ≥1:40 at Day 180 and Number of local reactions. Started May 2019; status: completed.
02
Drugs
OrthopoxVac
03
Conditions
smallpoxmpoxcowpoxvaccinia virus infection
Beyond the preview
Go deeper on NCT05762523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762523.